March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
October 2021 in “European urology open science” 4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
2 citations
,
April 2016 in “DOAJ (DOAJ: Directory of Open Access Journals)” The saw palmetto extract effectively inhibits an enzyme linked to prostate issues, showing promise for prostate health.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
26 citations
,
December 2023 in “Prostate International” Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
6 citations
,
August 2021 in “Clinical Epidemiology” Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
October 2006 in “Urology” Finasteride may help treat BPH by affecting certain biological markers.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
58 citations
,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
December 2023 in “Revista Urología Colombiana / Colombian Urology Journal” More research is needed to find effective treatments for sickle cell disease-related priapism.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” 39 citations
,
January 2008 in “World Journal of Gastroenterology” Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
June 2026 in “Precision medicine and engineering.” The hydrogel dressing RD@PVA helps heal diabetic wounds by reducing stress and improving blood vessel growth.
7 citations
,
October 2009 in “Journal of the American Geriatrics Society” Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.
May 2022 in “Endocrine Abstracts” Finasteride may cause sexual dysfunction by reducing epinephrine levels.
February 2013 in “Americanae (AECID Library)” Finasteride may reduce prostate tumor cell invasion and spread.
June 2019 in “Reactions Weekly” 78 citations
,
December 2008 in “The Journal of Sexual Medicine” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.